Lilly
Website to be confirmed.
About Lilly
A Radiopharma Developer player with a presence on the SNMMI floor; commercial activity worth a closer look.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- PR Newswire · 2026-06-19Lilly announces Phase II readout for lead theranostic candidateDetails remain limited but analysts read the move as a positioning play ahead of pivotal data.
- Nuclear Medicine Today · 2026-09-24Lilly expands cyclotron capacity to meet Lu-177 demandCoverage notes the company's growing footprint in the radioligand therapy space.
- STAT News · 2026-12-05Lilly signs supply agreement to support late-stage trialsThe announcement comes amid tightening Mo-99 and Lu-177 supply.
- Imaging Wire · 2026-03-26Lilly appoints new Chief Medical Officer ahead of pivotal trialCoverage notes the company's growing footprint in the radioligand therapy space.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
Actinium Pharmaceuticals
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Actinium Pharmaceuticals.
View profile →AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →Bayer Oncology
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Bayer Oncology.
View profile →